Biofrontera about to crush it come January

Discussion in 'Sun Pharma' started by anonymous, Sep 25, 2017 at 9:57 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    What makes you think it’s generic in October?
     

  2. anonymous

    anonymous Guest

    There is this new thing called "Google" maybe you should try it. Just type in "Levulan Patent Expiration"....what a dumbass
     
  3. anonymous

    anonymous Guest

    Try looking it up...October 2018 is when they lose the patent.
     
  4. anonymous

    anonymous Guest

    You dont turn anyone into FDA...it is the OIG office of inspector general. That is where I made my complaint and sent in my recordings. They can take up to 7 years to complete an investigation so dont expect anyone getting in trouble soon however if I were managers and upper management I wouldnt been sleeping well for a long time. These guys are very dirty.
     
  5. anonymous

    anonymous Guest


    Are u still with the company? If not can u say who u turned in?
     
  6. anonymous

    anonymous Guest

    Still here so cant say but it is a he and the tactics he suggested are off label and completely illegal. Selling the spread was recorded as well. I cant wait to leave.
     
  7. anonymous

    anonymous Guest

    They currently hold the positions of Prof. Relations Manager and NSD.
     
  8. anonymous

    anonymous Guest

    https://irpages2.eqs.com/websites/biofrontera/English/15/news-detail.html?newsID=1708151


    Biofrontera AG: Biofrontera AG subsidiary files suit against DUSA Pharmaceuticals, Inc

    DGAP-News: Biofrontera AG / Key word(s): Legal Matter

    12.07.2018 / 13:30
    The issuer is solely responsible for the content of this announcement.


    Biofrontera AG subsidiary files suit against DUSA Pharmaceuticals, Inc.

    Leverkusen, Germany, July 12, 2018 - Biofrontera Inc. ("Biofrontera"), a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), announced that on July 6, 2018, Biofrontera filed unfair competition and tortious interference claims against DUSA Pharmaceuticals, Inc. ("DUSA") in Orange County Superior Court in California.

    The lawsuit alleges that "DUSA provides excessive free product samples to physicians to offset their purchasing costs" in violation of federal law; that "DUSA has created an elaborate Average Sales Price scheme to inflate DUSA's product's profitability" in violation of state law; and that DUSA has improperly interfered with Biofrontera's relationships with one or more dermatology groups in violation of state law. The lawsuit seeks damages from and injunctive relief against DUSA.

    Three days later, on July 9, 2018, DUSA asserted trade secret misappropriation and tortious interference claims against Biofrontera in federal court in Massachusetts. DUSA's subsequent claims are without merit, and Biofrontera intends to vigorously fight them.

    -End-
     
  9. anonymous

    anonymous Guest

    Crazy German. SUN is 100% correct, anyone can lookup the details. ex employees taking confidential info equals a big jump start. #bettercheapermybutt. Off setting cost? #openbox #kettleblack #dumbmove #ruthlessDilipShanghvi. Doctors have similar stories about bf reps. #welcometothedarkside.
     
  10. anonymous

    anonymous Guest

    Please let us know where anyone can look it up.
     
  11. anonymous

    anonymous Guest

    This is just simple tit-for-tat jockeying by two companies who are so far out of the horse race that it’s ridiculous.

    Yes it started with reps leaving Sun (what else is new), and of course they take institutional knowledge including relationships and pricing along with their account lists. As more and more reps flew out the door, Sun dismissed it as ‘well, they weren’t good reps anyway’ - except for the ones who got big salary bumps to stay. And they left anyway. Sun knew back then that it was a problem, but in Indian-ego fashion, it was swept under the flying carpet.
    Now all the sudden they need to invoke litigation for people and patents. Well, it’s really too late for that (crack legal team, or is it legal team on crack). And then of course BF has to counter sue ... just keeping the legal boys busy.
     
  12. anonymous

    anonymous Guest

    Sun has still 90% market share. Why should they worry?

    Ameloose won't make any share in near future. Cant see it coming. Sun keeps all the big guys and leaves out the small derms for biofrontera which are not worth it anyway. And with the next price increase all big guys will buy Levulan again and make good extra bucks. No big guy buys Ameloose, no extra bucks.

    Compounding wont be an issue rest assured. Why should docs buy compounded stuff? No extra bucks neither! Extra bucks come only with Levulan.
     
  13. anonymous

    anonymous Guest

    Here’s why ALA manufacturers should worry:

    It’s not about the 90/10 split in share, it’s about the dramatic skid in ‘stick’ growth. Who cares what share is if the market growth is grinding down and pricing pressure is amping up. That’s a recipe for disaster, and that’s what’s happening. Sun can no longer offset the # sticks sold with higher and higher pricing, so their reliance on the Levulan profit stream must end.
     
  14. anonymous

    anonymous Guest

    No matter Levulan will be out of market soon or not, Ameloose wont even make it into the market more than 10/90.

    Better slowly dying at 90/10 than at 10/90. Dusa can cash out, Biofrontera must still cash in. For what? Silly German money.
     
  15. anonymous

    anonymous Guest

    come October compounds will flood the market due to patent expiration. game over
     
  16. anonymous

    anonymous Guest

    Why should docs use compounds? They cant bill compounds easily and earn way less with compounds. Docs are nut stupid. Compounds wont hurt Levulan coz less money for docs.
     
  17. anonymous

    anonymous Guest

    Generally agree.

    As Sun well knows, selling ‘the spread’ is where real money can be made, albeit illegal. The higher priced the product the more the DERM makes. Again, illegal to market ...
     
  18. anonymous

    anonymous Guest

    Therefore, a lower priced compounded product should theoretically not be as attractive to the DERM.
     
  19. anonymous

    anonymous Guest

    Does anybody know until when it must be decided by Dusa whether or not they will try another price increase?

    In my view kind of risky after being sued by Biofrontera. I guess that the OIG and Medicare will folow that sue very closely.

    Dont think Dusa will have the balls to make another price increase. But if they dont do it they will be out of business within 2 years. And they know that so maybe they dont care about the huge risks of selling the spread and do it again to do a final cash out and hurt Biofrontera badly again.
     
  20. anonymous

    anonymous Guest

    It was already decided in June and TG signed off on it as we had to load the massive inventory into distribution so that it shows being on the books (eg on the shelf) for 6 months (2 pricing cycles).
    That’s how Sun plays the game.

    #illegal